Drug-resistant pneumococcal pneumonia: clinical relevance and related factors.
暂无分享,去创建一个
J. Rello | F. Rodríguez de Castro | A. Torres | J. Blanquer | A. Fenoll | P. España | R. Zalacaín | O. Rajas | F. Rodríguez Salvanés | Antonio Vargas | J. Aspa | R. de Celis | P. España
[1] J. Castillo,et al. Bioestadística para las ciencias de la salud ( , 2004 .
[2] F. Baquero,et al. Antibiotic consumption and resistance selection in Streptococcus pneumoniae. , 2002, The Journal of antimicrobial chemotherapy.
[3] M. Jacobs. In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] P. Reiss,et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] J. Hutchinson. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. , 2002, The New England journal of medicine.
[6] R. Lütticken,et al. Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. , 2002, The Journal of antimicrobial chemotherapy.
[7] F. Baquero,et al. Antimicrobial Susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenesIsolates and Their Ecological Relationships: Results of a 1-Year (1998–1999) Multicenter Surveillance Study in Spain , 2001, Antimicrobial Agents and Chemotherapy.
[8] Susan R. Johnson,et al. Macrolide Resistance among Invasive Streptococcus Pneumoniae Isolates , 2022 .
[9] P. Rhomberg,et al. Antimicrobial Resistance among Clinical Isolates ofStreptococcus pneumoniae in the United States during 1999–2000, Including a Comparison of Resistance Rates since 1994–1995 , 2001, Antimicrobial Agents and Chemotherapy.
[10] V. Cheng,et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] M. Fine,et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. , 2001, American journal of respiratory and critical care medicine.
[12] M. Cetron,et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. , 2000, The New England journal of medicine.
[13] F. Baquero,et al. Influences of Different Factors on Prevalence of Ciprofloxacin Resistance in Streptococcus pneumoniae in Spain , 2000, Antimicrobial Agents and Chemotherapy.
[14] T. Marrie,et al. Molecular epidemiology of Streptococcus pneumoniae causing invasive disease in 5 countries. , 2000, The Journal of infectious diseases.
[15] Michael J Fine,et al. Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] A. Schuchat,et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. , 2000, Archives of internal medicine.
[17] A. Schuchat,et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. , 2000, American journal of public health.
[18] D. Felmingham,et al. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. , 2000, The Journal of antimicrobial chemotherapy.
[19] Mary Jane Ferraro,et al. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .
[20] Inger,et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. , 1997, The New England journal of medicine.
[21] J. Liñares,et al. Fluoroquinolone resistance in Streptococcus pneumoniae. , 1999, The New England journal of medicine.
[22] D E Low,et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. , 1999, The New England journal of medicine.
[23] J. Justman,et al. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] S. Dowell,et al. Failure of treatment of pneumonia associated with highly resistant pneumococci in a child. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[25] R. de Groot,et al. Hospital-related outbreak of infection with multidrug-resistant Streptococcus pneumoniae in the Netherlands. , 1999, The Journal of hospital infection.
[26] A. Torres,et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. , 1999, American journal of respiratory and critical care medicine.
[27] Pan‐Chyr Yang,et al. Extremely High Incidence of Macrolide and Trimethoprim-Sulfamethoxazole Resistance among Clinical Isolates ofStreptococcus pneumoniae in Taiwan , 1999, Journal of Clinical Microbiology.
[28] A. Rossi,et al. Risk Factors and Course of Illness Among Children With Invasive Penicillin-resistant Streptococcus pneumoniae , 1999 .
[29] F. Baquero,et al. Antimicrobial Resistance of 1,113Streptococcus pneumoniae Isolates from Patients with Respiratory Tract Infections in Spain: Results of a 1-Year (1996–1997) Multicenter Surveillance Study , 1999, Antimicrobial Agents and Chemotherapy.
[30] A. Rossi,et al. Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. The Streptococcus pneumoniae Working Group. , 1999, Pediatrics.
[31] F. Baquero,et al. Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: results of a 1-year (1996-1997) multicenter surveillance study. The Spanish Surveillance Group for Respiratory Pathogens. , 1999, Antimicrobial agents and chemotherapy.
[32] I. Jado,et al. Evolution of Streptococcus pneumoniaeSerotypes and Antibiotic Resistance in Spain: Update (1990 to 1996) , 1998, Journal of Clinical Microbiology.
[33] M. Pfaller,et al. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[34] E. Choi,et al. Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[35] G. Campbell,et al. Drug-resistant Streptococcus pneumoniae. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[36] S. Buckingham,et al. Breakthrough bacteremia and meningitis during treatment with cephalosporins parenterally for pneumococcal pneumonia. , 1998, The Journal of pediatrics.
[37] J. Córdoba-Doña,et al. Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[38] J. R. Parsons,et al. Bacteremia With Streptococcus pneumoniae: Implications for Therapy and Prevention , 1996 .
[39] R. Breiman,et al. Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention. Franklin County Pneumonia Study Group. , 1996, JAMA.
[40] S. Chevret,et al. Epidemiological features of and risk factors for infection by Streptococcus pneumoniae strains with diminished susceptibility to penicillin: findings of a French survey. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[41] I. Friedland. Comparison of the response to antimicrobial therapy of penicillin‐resistant and penicillin‐susceptible pneumococcal disease , 1995, The Pediatric infectious disease journal.
[42] C. Cabellos,et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. , 1995, The New England journal of medicine.
[43] E. Bouza,et al. Infections caused by erythromycin-resistant Streptococcus pneumoniae: incidence, risk factors, and response to therapy in a prospective study. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[44] J. Garau,et al. Predictive factors for invasive disease due to penicillin-resistant Streptococcus pneumoniae: a population-based study. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[45] A. Fenoll,et al. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989. , 1991, Reviews of infectious diseases.
[46] D. Hosmer,et al. Applied Logistic Regression , 1991 .
[47] David W. Hosmer,et al. Best subsets logistic regression , 1989 .
[48] Gordon Cook,et al. 11. Applied Categorical Data Analysis , 1988 .
[49] J. Enders,et al. Infectious Diseases Society of America. , 1969, Antimicrobial agents and chemotherapy.